ADA monotherapy or in combination with BTZ successfully inhibited the growth of CD138+ MM cells in RRMM patients who had experienced three cycles of BTZ-based regimes, evidencing a markedly resistance to BTZ that ADA could counteract (Figure 2B). This evidence concerns the gene SDC1 and Miyoshi myopathy.